Madison-based Exact Sciences' story illustrates that basic research — combined with hard work, strong teams and enough money ...

Shield is the first FDA-approved blood test for primary colorectal ... that would use blood samples to detect colorectal cancers. The device detects a colon cancer secreted protein known as ...

A blood-based test has acceptable accuracy for colorectal cancer detection but not for advanced precancerous lesions in an ...

Let’s make June a turning point where more people get screened, more cancers are caught early and fewer lives are lost.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.

Freenome plans to complete all modules of its premarket approval submission in mid-2025.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 ...

A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.